Summary & Overview
HCPCS J9260: Injection, Methotrexate Sodium, 50 mg
HCPCS Level II code J9260 denotes a 50 mg injectable dose of methotrexate sodium, a systemic antineoplastic and immunosuppressant used across oncology and certain autoimmune indications. Nationally, this code is used to capture the drug product and supports billing for outpatient and infusion-based administrations where parenteral chemotherapy or disease-modifying therapy is provided. Accurate coding of J9260 matters for clinical documentation, drug-cost reporting, and payer reimbursement consistency.
Key national payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for methotrexate injection, typical sites of service where J9260 is reported, common billing modifiers used with injectable drugs, and the typical payer mix involved in outpatient chemotherapy and specialty drug claims.
The publication provides benchmarks and coding guidance context, clarifies what information is and is not available in the source data, and outlines areas where policy updates or payer-specific rules commonly affect claim adjudication for injectable chemotherapeutics like methotrexate. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J9260 represents an injection of methotrexate sodium, 50 mg. This code describes a single-dose injectable administration of the chemotherapeutic and immunosuppressive agent methotrexate in a 50 mg quantity.
Service Type: Injection / Parenteral Drug Administration
Typical Site of Service: Outpatient clinic, physician office, hospital outpatient department, or infusion center, where injectable chemotherapy or specialty drug administrations are performed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 45-year-old female with rheumatoid arthritis who presents to an outpatient infusion clinic for a scheduled parenteral dose of methotrexate due to inadequate response or intolerance to oral therapy. The clinician reviews the most recent laboratory tests (CBC, liver function tests, serum creatinine) and confirms no contraindications. The medication is ordered as J9260 (methotrexate sodium, 50 mg), compounded or drawn by pharmacy or nursing and administered via intramuscular or subcutaneous injection depending on the prescription. Nursing documents the dose, route, lot number, expiration, and patient tolerance in the medical record. Observation for immediate adverse reactions occurs for a short period post-injection. Billing is submitted using J9260 with an appropriate modifier to indicate circumstances such as bilateral procedures, discontinued services, or administration-related distinctions. Typical sites of service include outpatient infusion centers, physician offices, and ambulatory care clinics. Patient education about side effects, folic acid supplementation, and follow-up laboratory monitoring is provided as part of the clinical workflow.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug discarded/not administered to any patient | When part of the vial is wasted or discarded and must be reported separately from the administered portion |